Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Liabilities and Shareholders Equity (2022 - 2025)

Historic Liabilities and Shareholders Equity for Atara Biotherapeutics (ATRA) over the last 4 years, with Q3 2025 value amounting to $30.2 million.

  • Atara Biotherapeutics' Liabilities and Shareholders Equity fell 7886.07% to $30.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $238.2 million, marking a year-over-year decrease of 5967.86%. This contributed to the annual value of $109.1 million for FY2024, which is 3408.14% down from last year.
  • According to the latest figures from Q3 2025, Atara Biotherapeutics' Liabilities and Shareholders Equity is $30.2 million, which was down 7886.07% from $36.9 million recorded in Q2 2025.
  • Over the past 5 years, Atara Biotherapeutics' Liabilities and Shareholders Equity peaked at $436.1 million during Q2 2022, and registered a low of $30.2 million during Q3 2025.
  • Over the past 4 years, Atara Biotherapeutics' median Liabilities and Shareholders Equity value was $165.5 million (recorded in 2023), while the average stood at $209.6 million.
  • Per our database at Business Quant, Atara Biotherapeutics' Liabilities and Shareholders Equity plummeted by 2396.22% in 2023 and then plummeted by 7886.07% in 2025.
  • Over the past 4 years, Atara Biotherapeutics' Liabilities and Shareholders Equity (Quarter) stood at $376.4 million in 2022, then crashed by 56.03% to $165.5 million in 2023, then tumbled by 34.08% to $109.1 million in 2024, then tumbled by 72.35% to $30.2 million in 2025.
  • Its last three reported values are $30.2 million in Q3 2025, $36.9 million for Q2 2025, and $62.0 million during Q1 2025.